Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $308.5 million.

  • Amicus Therapeutics' Shares Outstanding (Weighted Average) rose 123.99% to $308.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.5 million, marking a year-over-year increase of 123.99%. This contributed to the annual value of $304.4 million for FY2024, which is 312.23% up from last year.
  • Per Amicus Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $308.5 million for Q3 2025, which was up 123.99% from $308.3 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Shares Outstanding (Weighted Average) peaked at $308.5 million during Q3 2025, and registered a low of $266.4 million during Q2 2021.
  • For the 5-year period, Amicus Therapeutics' Shares Outstanding (Weighted Average) averaged around $295.4 million, with its median value being $295.8 million (2023).
  • In the last 5 years, Amicus Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 649.73% in 2022 and then soared by 98.97% in 2023.
  • Over the past 5 years, Amicus Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $271.4 million in 2021, then increased by 6.5% to $289.1 million in 2022, then increased by 2.11% to $295.2 million in 2023, then increased by 3.12% to $304.4 million in 2024, then increased by 1.34% to $308.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $308.5 million in Q3 2025, compared to $308.3 million in Q2 2025 and $307.7 million in Q1 2025.